EPHX2
ENSG00000120915
Target class
Enzyme
Chromosome
8
Approved drugs
0
Clinical candidates (approved and in development)
2
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- Yes
- Target name
- EPHX2
- Gene name
- Epoxide hydrolase 2
- Gene symbol
- EPHX2
- Protein name
- Bifunctional epoxide hydrolase 2 [Includes: Cytosolic epoxide hydrolase 2 (CEH) (EC 3.3.2.10) (Epoxide hydratase) (Soluble epoxide hydrolase) (SEH); Lipid-phosphate phosphatase (EC 3.1.3.76)]
- ABHD20
- sEH
- Gene biotype
- Protein coding
- Gene family
- Abhydrolase domain containing|HAD Asp-based non-protein phosphatases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 86.54
- Tissue specificity (Gini)
- 0.391
- Tissue specificity (tau)
- 0.763
- KEGG gene identifiers
- hsa:2053
- Protein interaction confidence
- 0.829038
- Protein interaction partners
- 52
- R-HSA-2142670
- R-HSA-9018682
- R-HSA-9033241
- End position
- 27548992
- Start position
- 27490775
- Chromosome
- 8
- Strand
- Forward
- Cytoplasm. Peroxisome.
- Cytosol
- Tissue specificity (tau)
- 0.763248
- Expression inequality (Gini)
- 0.391403
Expression in transcripts per million
- Liver
- 86.54
- Adrenal Gland
- 61.99
- Kidney - Medulla
- 53.04
- Prostate
- 48.99
- Pituitary
- 44.91
Expression in transcripts per million
- Liver86.54
- Adrenal Gland61.99
- Kidney - Medulla53.04
- Prostate48.99
- Pituitary44.91
- Ovary40.8
- Small Intestine - Terminal Ileum40.02
- Kidney - Cortex39.55
- Skin - Not Sun Exposed (Suprapubic)38.99
- Skin - Sun Exposed (Lower leg)37.46
- Colon - Transverse35.68
- Fallopian Tube33.82
- Esophagus - Mucosa31.97
- Cervix - Ectocervix28.94
- Cervix - Endocervix28.74
- Uterus27.59
- Thyroid27.08
- Vagina26.36
- Colon - Sigmoid25.93
- Bladder23.51
- Pancreas23.17
- Breast - Mammary Tissue21.49
- Esophagus - Gastroesophageal Junction18.55
- Minor Salivary Gland17.4
- Esophagus - Muscularis17.01
And 29 more, listed on the interactive page.
- GO:0001558
- GO:0010628
- GO:0016311
- GO:0042632
- GO:0046272
- GO:0046839
- GO:0090181
- GO:0097176
- GO:0005777
- GO:0005782
- GO:0005829
- GO:0070062
- GO:0000287
- GO:0004301
- GO:0015643
- GO:0016791
- GO:0033885
- GO:0042577
- GO:0042803
- GO:0052642
Related records
Trials (305)
- "Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
- [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
- 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
- A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer
- A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer
- A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
- A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
- A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer
- A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
- A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma
- A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
- A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
- A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?
- A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
- A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
- A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer
- A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Drugs (5)
- AR9281 Epoxide hydratase inhibitor
- GSK2256294 Epoxide hydratase inhibitor
- Oxaprozin
- Regorafenib
- Zafirlukast